CLAIMS

1. Use of an oncolytic virus selected from the group consisting of Delta-24 and Delta-24 RGD in the manufacture of a medicament for treating cancer in a patient having or suspected of having a primary or metastatic brain tumor and being treated with a Th1 stimulating agent.

2. Use of a Th1 stimulating agent in the manufacture of a medicament for treating cancer in a patient having or suspected of having a primary or metastatic brain tumor and being treated with an oncolytic virus selected from the group consisting of Delta-24 and Delta-24 RGD.

3. The use of claims 1-2, wherein said Th1 stimulating agent is an agent which upregulates or activates the cellular immune system.

4. The use of claim 3, wherein said agent which upregulates or activates the cellular immune system is a cytokine selected from the group consisting of recombinant IL-12p70 and recombinant IFN-gamma.

5. The use of claim 3, wherein said agent which upregulates or activates the cellular immune system is an agent selected from the group consisting of Revlimid and lenadlidomide.

6. The use of claims 1-2, wherein said Th1 stimulating agent is an agent which suppresses regulatory T cells.

7. The use of claim 6, wherein the agent which suppresses regulatory T cells is selected from the group consisting of temozolomide (4-methyl-5-oxo- 2,3,4,6,8-pentazabicyclo [4.3.0] nona-2,7,9-triene- 9-carboxamide), cyclophosphamide ((RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine-2-oxide), lomustine (CCNU;

N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea), bis-chloroethylnitrosourea (BCNU), melphalan hydrochloride (4[bis(chloroethyl)amino]phenylalanine), and busulfan (butane-1,4-diyl dimethanesulfonate).

8. The use of claims 1-2, wherein said Th1 stimulating agent is an agent which is an antagonist of a suppressor of cellular immunity.

9. The use of claim 8, wherein said agent which is an antagonist of a suppressor of cellular immunity is an antagonist of CTLA-4.

10. The use of claim 9, wherein said agent is selected from the group consisting of Ipilimumab, MDX-010, MDX-101, Tremelimumab, and CP-675,206.

11. The use of claims 8, wherein said agent which is an antagonist of a suppressor of cellular immunity is a PD-1/PD-L1 receptor antagonist.

12. The use of claim 11, wherein said agent is selected from the group consisting of MDX-1106, MK-3475, AMP-224, Pidilizumab, and MDX-1105.

13. The use of claims 1-12, wherein the virus is to be administered intratumorally.

14. The use of claim 13, wherein the virus is to be administered intratumorally by injection into multiple tumor sites.

15. The use of claims 1-12, wherein the virus is to be administered intravascularly, such as intravenously or intraarterially.

16. The use of claims 1-12, wherein said brain tumor is a glioma.

17. The use of claim 16, wherein the glioma is low-grade glioma.

18. The use of claim 16, wherein the glioma is high-grade glioma.

19. The use of claims 1-18, wherein the oncolytic virus is to be administered to the patient prior to the Th1 stimulating agent.

20. The use of claims 1-18, wherein the oncolytic virus is to be administered to the patient after the Th1 stimulating agent.

21. The use of claims 1-12, where the brain tumor is primary brain tumor.

22. The use of claims 1-12, where the brain tumor is metastatic brain tumor.